Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) is a company that focuses in the provision of electronic health and practice management services. The business guru serves a wide range of healthcare providers and works towards enhancing service delivery. It was today that the company disclosed details about its collaboration with Rothman Orthopaedic Institute.
The two business giants join hands in a quest to provide Allscripts® Practice Management in the whole of Pennsylvania.
A close outlook
Sources indicate that Rothman Institute saw it fit to settle for Allscripts Practice Management. It sees this as the most ideal choice and thus takes it as its main financial platform. It hopes this serves as a perfect replacement for its legacy system.
Allscripts PM at the moment works towards assisting Rothman Institute move smoothly with its wide range of activities. Those include managing collections, scheduling, denials and claims. At the same time, it also seeks to ensure the organization’s revenue increases by a significant margin.
Rothman Orthopaedic Institute has undergone major expansions over the years. Currently, it takes immense pride in having established a lot of locations. It has locations in New York, New Jersey and above all Pennsylvania. At this point in time, it sticks out as one of the global leaders in orthopedic science and technology.
The turn of events
The Institute’s clinical team works for the Philadelphia 76ers, Philadelphia Flyers and the Philadelphia Eagles as well.
The Chief Information Officer of Rothman Orthopaedic Lancer Seaman opined, “The Allscripts Practice Management solution is helping us improve our financial and operational performance. Our staff felt prepared, well trained and confident at go-live, and the Allscripts onsite team did a great job of helping us through the transition week for a smooth, successful go-live.”
The General Manager of the Practice Management segment working with Allscripts, Tina Joros, has spoken in relation to the matter. The leader applauds the company for most of its recent moves. Above all, the official commends teams from both Allscript and Rothman Institute for their dedication and commitment in the undertaking.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.